The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma

Barr, 2008, Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation, Curr. Opin. Oncol., 20, 502, 10.1097/CCO.0b013e32830b61ac Bende, 2007, Molecular pathways in follicular lymphoma, Leukemia, 21, 18, 10.1038/sj.leu.2404426 Bidere, 2009, Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival, Nature, 458, 92, 10.1038/nature07613 Calado, 2010, Constitutive canonical NF-kappaB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma, Cancer Cell, 18, 580, 10.1016/j.ccr.2010.11.024 Chin, 2008, Translating insights from the cancer genome into clinical practice, Nature, 452, 553, 10.1038/nature06914 Compagno, 2009, Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma, Nature, 459, 717, 10.1038/nature07968 Dawson, 2007, Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas, Oncogene, 26, 4243, 10.1038/sj.onc.1210211 Dickins, 2005, Probing tumor phenotypes using stable and regulated synthetic microRNA precursors, Nat. Genet., 37, 1289, 10.1038/ng1651 Ding, 2008, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, 455, 1069, 10.1038/nature07423 Egle, 2004, VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia, Blood, 103, 2276, 10.1182/blood-2003-07-2469 Feldser, 2010, Stage-specific sensitivity to p53 restoration during lung cancer progression, Nature, 468, 572, 10.1038/nature09535 Gaidano, 1992, Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma, Blood, 80, 1781, 10.1182/blood.V80.7.1781.1781 Hauptschein, 1998, Cloning and mapping of human chromosome 6q26-q27 deleted in B-cell non-Hodgkin lymphoma and multiple tumor types, Genomics, 50, 170, 10.1006/geno.1998.5321 Heyer, 2010, Non-germline genetically engineered mouse models for translational cancer research, Nat. Rev. Cancer, 10, 470, 10.1038/nrc2877 Himanen, 2010, Architecture of Eph receptor clusters, Proc. Natl. Acad. Sci. USA, 107, 10860, 10.1073/pnas.1004148107 Holmberg, 2000, Regulation of repulsion versus adhesion by different splice forms of an Eph receptor, Nature, 408, 203, 10.1038/35041577 Johnson, 2009, Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival, Blood, 114, 2273, 10.1182/blood-2009-03-212191 Kato, 2009, Frequent inactivation of A20 in B-cell lymphomas, Nature, 459, 712, 10.1038/nature07969 Klein, 2008, Germinal centres: role in B-cell physiology and malignancy, Nat. Rev. Immunol., 8, 22, 10.1038/nri2217 Kuang, 2010, Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia, Blood, 115, 2412, 10.1182/blood-2009-05-222208 Lenz, 2008, Oncogenic CARD11 mutations in human diffuse large B cell lymphoma, Science, 319, 1676, 10.1126/science.1153629 Macrae, 2005, A conditional feedback loop regulates Ras activity through EphA2, Cancer Cell, 8, 111, 10.1016/j.ccr.2005.07.005 Maloney, 2003, Rituximab for follicular lymphoma, Curr. Hematol. Rep., 2, 13 Mandelbaum, 2010, BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma, Cancer Cell, 18, 568, 10.1016/j.ccr.2010.10.030 Mavrakis, 2010, Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia, Nat. Cell Biol., 12, 372, 10.1038/ncb2037 McBride, 2008, Regulation of class switch recombination and somatic mutation by AID phosphorylation, J. Exp. Med., 205, 2585, 10.1084/jem.20081319 McCaffrey, 2002, RNA interference in adult mice, Nature, 418, 38, 10.1038/418038a Nanjangud, 2007, Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression, Cytogenet. Genome Res., 118, 337, 10.1159/000108318 Ngo, 2011, Oncogenically active MYD88 mutations in human lymphoma, Nature, 470, 115, 10.1038/nature09671 Noren, 2006, The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway, Nat. Cell Biol., 8, 815, 10.1038/ncb1438 Novak, 2009, The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas, Blood, 113, 4918, 10.1182/blood-2008-08-174110 Offit, 1993, 6q deletions define distinct clinico-pathologic subsets of non-Hodgkin's lymphoma, Blood, 82, 2157, 10.1182/blood.V82.7.2157.2157 Oricchio, 2010, Mouse models of cancer as biological filters for complex genomic data, Dis. Model Mech., 11-12, 701, 10.1242/dmm.006296 Pasquale, 2008, Eph-ephrin bidirectional signaling in physiology and disease, Cell, 133, 38, 10.1016/j.cell.2008.03.011 Pasquale, 2010, Eph receptors and ephrins in cancer: bidirectional signalling and beyond, Nat. Rev. Cancer, 10, 165, 10.1038/nrc2806 Pasqualucci, 2006, Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma, J. Exp. Med., 203, 311, 10.1084/jem.20052204 Relander, 2010, Prognostic factors in follicular lymphoma, J. Clin. Oncol., 28, 2902, 10.1200/JCO.2009.26.1693 Schmitz, 2009, TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma, J. Exp. Med., 206, 981, 10.1084/jem.20090528 Seiradake, 2010, An extracellular steric seeding mechanism for Eph-ephrin signaling platform assembly, Nat. Struct. Mol. Biol., 17, 398, 10.1038/nsmb.1782 Shaffer, 2008, IRF4 addiction in multiple myeloma, Nature, 454, 226, 10.1038/nature07064 Smith, 2004, Dissecting the EphA3/Ephrin-A5 interactions using a novel functional mutagenesis screen, J. Biol. Chem., 279, 9522, 10.1074/jbc.M309326200 Valenzuela, 1995, Identification of full-length and truncated forms of Ehk-3, a novel member of the Eph receptor tyrosine kinase family, Oncogene, 10, 1573 Velculescu, 2008, Defining the blueprint of the cancer genome, Carcinogenesis, 29, 1087, 10.1093/carcin/bgn096 Ventura, 2007, Restoration of p53 function leads to tumour regression in vivo, Nature, 445, 661, 10.1038/nature05541 Viardot, 2002, Clinicopathologic correlations of genomic gains and losses in follicular lymphoma, J. Clin. Oncol., 20, 4523, 10.1200/JCO.2002.12.006 Wendel, 2004, Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy, Nature, 428, 332, 10.1038/nature02369 Xue, 2007, Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, 445, 656, 10.1038/nature05529 Zender, 2008, An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer, Cell, 135, 852, 10.1016/j.cell.2008.09.061 Antipenko, A., Himanen, J.P., van Leyen, K., Nardi-Dei, V., Lesniak, J., Barton, W.A., Rajashankar, K.R., Lu, M., Hoemme, C., Puschel, A.W., et al. (2003). Structure of the semaphorin-3A receptor binding module. Neuron 39, 589–598. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J., and Hanahan, D. (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808–812. Chen, K., McLellan, M.D., Ding, L., Wendl, M.C., Kasai, Y., Wilson, R.K., and Mardis, E.R. (2007). PolyScan: an automatic indel and SNP detection approach to the analysis of human resequencing data. Genome Res. 17, 659–666. Dickins, R.A., Hemann, M.T., Zilfou, J.T., Simpson, D.R., Ibarra, I., Hannon, G.J., and Lowe, S.W. (2005). Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289–1295. Egle, A., Harris, A.W., Bath, M.L., O'Reilly, L., and Cory, S. (2004). VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 103, 2276–2283. Gordon, D., Abajian, C., and Green, P. (1998). Consed: a graphical tool for sequence finishing. Genome Res. 8, 195–202. Himanen, J.P., Henkemeyer, M., and Nikolov, D.B. (1998). Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2. Nature 396, 486–491. Mandelbaum, J., Bhagat, G., Tang, H., Mo, T., Brahmachary, M., Shen, Q., Chadburn, A., Rajewsky, K., Tarakhovsky, A., Pasqualucci, L., et al. (2010). BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell Lymphoma. Cancer Cell 18, 568–579. Mavrakis, K.J., Wolfe, A.L., Oricchio, E., Palomero, T., de Keersmaecker, K., McJunkin, K., Zuber, J., James, T., Khan, A.A., Leslie, C.S., et al. (2010). Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T cell acute lymphoblastic leukemia. Nat. Cell Biol. 12, 372–379. Mavrakis, K.J., Zhu, H., Silva, R.L., Mills, J.R., Teruya-Feldstein, J., Lowe, S.W., Tam, W., Pelletier, J., and Wendel, H.G. (2008). Tumorigenic activity and therapeutic inhibition of Rheb GTPase. Genes Dev. 22, 2178–2188. McBride, K.M., Gazumyan, A., Woo, E.M., Schwickert, T.A., Chait, B.T., and Nussenzweig, M.C. (2008). Regulation of class switch recombination and somatic mutation by AID phosphorylation. J. Exp. Med. 205, 2585–2594. Nickerson, D.A., Tobe, V.O., and Taylor, S.L. (1997). PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res. 25, 2745–2751. Scott, C.L., Gil, J., Hernando, E., Teruya-Feldstein, J., Narita, M., Martinez, D., Visakorpi, T., Mu, D., Cordon-Cardo, C., Peters, G., et al. (2007). Role of the chromobox protein CBX7 in lymphomagenesis. Proc. Natl. Acad. Sci. USA 104, 5389–5394. Shaknovich, R., Figueroa, M.E., and Melnick, A. (2010). HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. Methods Mol. Biol. 632, 191–201. Thompson, R.F., Reimers, M., Khulan, B., Gissot, M., Richmond, T.A., Chen, Q., Zheng, X., Kim, K., and Greally, J.M. (2008). An analytical pipeline for genomic representations used for cytosine methylation studies. Bioinformatics 24, 1161–1167. Veeriah, S., Taylor, B.S., Meng, S., Fang, F., Yilmaz, E., Vivanco, I., Janakiraman, M., Schultz, N., Hanrahan, A.J., Pao, W., et al. (2010). Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat. Genet. 42, 77–82. Wendel, H.G., de Stanchina, E., Cepero, E., Ray, S., Emig, M., Fridman, J.S., Veach, D.R., Bornmann, W.G., Clarkson, B., McCombie, W.R., et al. (2006). Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc. Natl. Acad. Sci. USA 103, 7444–7449. Wendel, H.G., De Stanchina, E., Fridman, J.S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., and Lowe, S.W. (2004). Survival signaling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–337. Xu, K., Rajashankar, K.R., Chan, Y.P., Himanen, J.P., Broder, C.C., and Nikolov, D.B. (2008). Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc. Natl. Acad. Sci. USA 105, 9953–9958. Yu, D., and Thomas-Tikhonenko, A. (2002). A non-transgenic mouse model for B cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene 21, 1922–1927.